AL amyloidosis interactive patient journey
Join Dr Shaji Kumar (Mayo Clinic in Rochester, Minnesota, USA) in this interactive patient journey, and explore case-based approaches to managing AL amyloidosis. Review the patient’s symptoms and strategies in management to make informed decisions, navigate challenges that arise, and learn how to overcome them for a positive outcome.
| Patient Biography | |
| Name | Jane |
| Age | 58 |
| Gender | Female |
| Occupation | Retired teacher |
| Initial Symptoms | Fatigue, dyspnoea, swelling in ankles, peripheral neuropathy |
If you do not see a window below, please ensure cookies are enabled and then refresh your browser. If you still do not see a window, please also disable any ad-blockers.
Meet the expert
Dr Shaji Kumar, MD, is a consultant in the Division of Hematology, and Mark and Judy Mullins Professor of Hematological Malignancies at Mayo Clinic in Rochester, Minnesota, USA. He is Chair of the Myeloma, Amyloidosis and Dysproteinemia Disease Group at the Mayo Clinic, and Research Chair for the Division of Hematology. Dr Kumar’s research focuses on the development of novel drugs and drug combinations for myeloma. His laboratory focuses on the role of the bone marrow microenvironment in the development of myeloma. Dr Kumar is Chair of the National Comprehensive Cancer Network (NCCN) Multiple Myeloma Guidelines Panel.
Disclosures
Clinical trial funding: AbbVie, Amgen, Allogene, Bristol Myers Squibb, CARsgen, GSK, Janssen, Regeneron, Roche–Genentech, Takeda.
Consulting/advisory board participation (no personal payments): AbbVie, ArcellX, BeiGene, Bristol Myers Squibb, K36 Therapeutics, Janssen, Loxo Oncology, Pfizer, Roche–Genentech, Sanofi, Takeda.
Developed independently by EPG Health who received educational funding from Alexion in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.